Takeda Pharmaceutical (TAK) Total Non-Current Liabilities (2017 - 2026)

Takeda Pharmaceutical's Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $33.5 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 6.25% year-over-year to $33.5 billion; the TTM figure through Mar 2026 stood at $33.5 billion (up 6.25% YoY), while the FY2026 annual figure was $34.9 billion, up 10.52% from the prior year.
• Total Non-Current Liabilities was $33.5 billion for Q1 2026 at Takeda Pharmaceutical, roughly flat from $33.5 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $46.0 billion in Q1 2022 to a low of $31.5 billion in Q1 2025.
• Historically, Total Non-Current Liabilities has averaged $37.1 billion across 5 years, with a median of $36.8 billion in 2024.
• The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities declined 26.29% in 2022, then gained 6.25% in 2026.
• A 5-year view of Total Non-Current Liabilities shows it stood at $36.0 billion in 2022, then dropped by 2.42% to $35.2 billion in 2023, then increased by 4.55% to $36.8 billion in 2024, then decreased by 8.91% to $33.5 billion in 2025, then fell by 0.07% to $33.5 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $33.5 billion (Q1 2026), $33.5 billion (Q4 2025), and $35.3 billion (Q3 2025), per Business Quant data.